CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: ZNF500 (ImmuneEditome ID:26048)

1. Gene summary of enriched editing regions for ZNF500

check button Gene summary
Gene informationGene symbol

ZNF500

Gene ID

26048

GeneSynonymsZKSCAN18|ZSCAN50
GeneCytomap

16p13.3

GeneTypeprotein-coding
GeneDescriptionzinc finger protein 500|zinc finger protein with KRAB and SCAN domains 18
GeneModificationdate20230517
UniprotIDO60304;K7ERS9;K7EM64;K7EPZ1;K7EIH1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:4749607-4751921:-ENST00000545009.1ENSG00000103199.12ZNF500exonicAluJo,AluSc5,MLT1C,AluSpchr16:4749607-4751921:-.alignment


Top

2. Tumor-specific enriched editing regions for ZNF500


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
ENSG00000103199.12,ZNF500COADEAG1.1454e-02image
chr16:4749607-4751921:-LUSCEER7.3205e-05image
ENSG00000103199.12,ZNF500LUSCEAG7.3386e-05image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr16:4749607-4751921:-KIRCPathEER1.9373e-031.2087e-03-0.1490image
ENSG00000103199.12,ZNF500KIRCPathEAG1.8255e-031.1309e-03-0.1499image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
ENSG00000103199.12,ZNF500HNSCEAG2.6075e-024.0002e-022.1235e-01image

Top

3. Enriched editing regions and immune related genes for ZNF500


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:4749607-4751921:-GBMEERENSG00000231234,SKP1P10.29938.6825e-031.2269e-070.4023imageNNNAMacrophages_M0GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr16:4749607-4751921:-GBMEERENSG00000067601,PMS2P40.24583.9715e-022.2570e-110.4959imageNNNAPlasma_cellsGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr16:4749607-4751921:-GBMEERENSG00000134020,PEBP40.24224.6388e-021.0324e-070.4044imageNADAR;CSTF2T;DGCR8;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPC;IGF2BP2;KHDRBS1;NOP56;NOP58;RBFOX2;SRSF1;SRSF3;TAF15;TARDBP;U2AF2NAPlasma_cellsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr16:4749607-4751921:-UCECEERENSG00000169564,PCBP10.45791.0788e-051.6853e-080.4206imageNACIN1;ADAR;AIFM1;BUD13;CPSF6;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;IGF2BP2;KHDRBS1;KHDRBS2;LIN28;MOV10;NOP56;NOP58;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SLTM;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;U2AF2;YWHAG;ZNF184;FXR1;FXR2;HNRNPK;NUMA1;RBM22;SF3A3;SMNDC1;TIA1;TIAL1;U2AF1PCBP1T_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr16:4749607-4751921:-UCECEERENSG00000115806,GORASP20.44941.8037e-053.1461e-080.4132imageNADAR;AIFM1;BUD13;CPSF6;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FTO;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;IGF2BP2;KHDRBS1;KHDRBS2;LIN28;MOV10;NOP56;NOP58;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SLTM;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;U2AF2;YWHAG;ZNF184;FXR1;FXR2;HNRNPK;NUMA1;RBM22;SF3A3;SMNDC1;TIA1;TIAL1;U2AF1NAT_cells_CD8GSVA_HALLMARK_PROTEIN_SECRETION
chr16:4749607-4751921:-UCECEERENSG00000254612,RP11-676M6.10.43355.5192e-054.3800e-080.4093imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_HEME_METABOLISM
chr16:4749607-4751921:-UCECEERENSG00000140688,C16orf580.42927.5614e-051.6279e-080.4210imageNACIN1;ADAR;AIFM1;BUD13;CPSF6;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FTO;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;IGF2BP2;KHDRBS1;KHDRBS2;LIN28;MOV10;NOP56;NOP58;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SLTM;SRSF1;SRSF3;SRSF9;TAF15;TARDBP;U2AF2;YWHAG;ZNF184;FXR1;FXR2;HNRNPK;NUMA1;RBM22;SF3A3;SMNDC1;TIA1;TIAL1;U2AF1NAMonocytesGSVA_HALLMARK_HEME_METABOLISM
chr16:4749607-4751921:-UCECEERENSG00000115762,PLEKHB20.40043.1356e-048.3417e-080.4014imageNACIN1;ADAR;AIFM1;BUD13;CPSF6;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FTO;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;IGF2BP2;KHDRBS1;KHDRBS2;LIN28;MOV10;NOP56;NOP58;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SLTM;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;U2AF2;YWHAG;ZNF184;FXR1;FXR2;HNRNPK;NUMA1;RBM22;SF3A3;SMNDC1;TIA1;TIAL1;U2AF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr16:4749607-4751921:-UCECEERENSG00000161011,SQSTM10.36971.2646e-037.0937e-090.4305imageNACIN1;ADAR;AIFM1;BUD13;CPSF6;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FTO;FUS;HNRNPA1;HNRNPA2B1;HNRNPC;IGF2BP2;KHDRBS1;KHDRBS2;LIN28;MOV10;NOP56;NOP58;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SLTM;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;U2AF2;YWHAG;ZNF184;FXR1;FXR2;HNRNPK;NUMA1;RBM22;SF3A3;SMNDC1;TIA1;TIAL1;U2AF1SQSTM1NK_cells_restingGSVA_HALLMARK_HEME_METABOLISM
chr16:4749607-4751921:-UCECEERENSG00000147050,KDM6A0.35632.1206e-035.6018e-080.4063imageNACIN1;ADAR;AIFM1;BUD13;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;FTO;FUS;HNRNPA1;HNRNPC;IGF2BP2;KHDRBS1;KHDRBS2;LIN28;MOV10;NOP56;NOP58;PRPF8;RANGAP1;RBFOX2;RBM10;SLTM;SRSF1;SRSF10;SRSF3;SRSF9;TAF15;TARDBP;U2AF2;ZNF184;FXR2;HNRNPK;RBM22;SF3A3;SMNDC1;TIA1;TIAL1;U2AF1NAT_cells_CD4_memory_restingGSVA_HALLMARK_UV_RESPONSE_DN

More results



Top

4. Enriched editing regions and immune related splicing for ZNF500


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000103199.12,ZNF500
ACCEAGMEXENSG00000120685.15chr1339012082:39012233:39012690:39012821:39013489:39014476:39017499:39017544-0.64712.7697e-022.3007e-07-0.5864imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000103199.12,ZNF500
ACCEAGMEXENSG00000120685.15chr1339012082:39012233:39012690:39012821:39014298:39014476:39017499:39017544-0.64712.7697e-022.3007e-07-0.5864imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000103199.12,ZNF500
ACCEAGMEXENSG00000168374.6chr357571404:57572298:57575547:57575673:57584383:57584464:57597073:57597198-0.66142.7697e-028.4539e-07-0.5634imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000103199.12,ZNF500
ACCEAGMEXENSG00000013561.13chr5141973582:141973742:141974803:141974955:141983381:141983552:141984802:1419849330.65692.7697e-024.1507e-070.5762imageNACIN1;ALYREF;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAT_cells_CD8GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000103199.12,ZNF500
ACCEAGA3ENSG00000151148.9chr12109489918:109490004:109491044:109491127:109490489:1094911270.58913.4473e-025.0637e-070.6001imageNAIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000103199.12,ZNF500
ACCEAGIRENSG00000196914.4chr11120477446:120477526:120478155:120478389-0.57524.0407e-021.1157e-03-0.4174imageNACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184ARHGEF12GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000103199.12,ZNF500
ACCEAGMEXENSG00000113312.6chr5160009112:160009193:160010499:160010858:160051128:160051183:160064931:1600650220.65294.0407e-022.3458e-080.6228imageNACIN1;AIFM1;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM5;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAGNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000103199.12,ZNF500
ACCEAGA3ENSG00000166451.9chr1681020099:81020276:81022754:81022874:81022596:81022874-0.61164.0407e-021.5377e-07-0.6007imageNACIN1;ALYREF;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000103199.12,ZNF500
ACCEAGMEXENSG00000096384.15chr644247086:44247195:44248629:44248776:44252162:44252267:44253044:442533780.64194.0407e-021.1291e-090.6650imageNACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YWHAG;ZNF184HSP90AB1T_cells_CD8GSVA_HALLMARK_PROTEIN_SECRETION
chr16:4749607-4751921:-
CESCEERIRENSG00000129696.8chr833498953:33499277:33500327:335004900.46835.4340e-101.7514e-130.4329imageNACIN1;ADAR;BUD13;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FBL;HNRNPA1;HNRNPC;IGF2BP2;KHDRBS1;LIN28;MOV10;NOP56;NOP58;PRPF8;RANGAP1;RBFOX2;RBM10;RBM27;SLTM;SRSF1;SRSF3;TAF15;TARDBP;U2AF2;ZNF184;FXR1;FXR2;RBM22;TIA1;U2AF1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for ZNF500


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
ENSG00000103199.12,ZNF500ACCEAGT_cells_follicular_helper1.8272e-02-0.2898image
chr16:4749607-4751921:-BLCAEERMast_cells_activated4.2686e-030.1548image
ENSG00000103199.12,ZNF500BLCAEAGMast_cells_activated4.2686e-030.1548image
chr16:4749607-4751921:-BRCAEERT_cells_CD4_memory_resting1.4757e-040.1167image
ENSG00000103199.12,ZNF500BRCAEAGT_cells_CD4_memory_resting1.8293e-040.1150image
chr16:4749607-4751921:-CESCEERMacrophages_M02.0984e-030.1885image
ENSG00000103199.12,ZNF500CESCEAGMacrophages_M02.1064e-030.1884image
ENSG00000103199.12,ZNF500COADEAGT_cells_CD82.8313e-02-0.1528image
ENSG00000103199.12,ZNF500DLBCEAGB_cells_memory2.0539e-02-0.3651image
chr16:4749607-4751921:-GBMEERPlasma_cells1.0171e-100.4814image
ENSG00000103199.12,ZNF500GBMEAGPlasma_cells1.0478e-100.4811image
ENSG00000103199.12,ZNF500HNSCEAGT_cells_CD83.5691e-04-0.1829image
ENSG00000103199.12,ZNF500KICHEAGEosinophils5.9531e-040.4240image
chr16:4749607-4751921:-KIRCEERT_cells_regulatory_(Tregs)2.0561e-03-0.1644image
ENSG00000103199.12,ZNF500KIRCEAGT_cells_regulatory_(Tregs)1.7451e-03-0.1670image
ENSG00000103199.12,ZNF500KIRPEAGB_cells_naive8.2446e-050.2440image
ENSG00000103199.12,ZNF500LAMLEAGT_cells_follicular_helper3.1053e-020.2327image
chr16:4749607-4751921:-LGGEERDendritic_cells_activated1.1010e-020.1107image
ENSG00000103199.12,ZNF500LGGEAGDendritic_cells_activated1.1010e-020.1107image
chr16:4749607-4751921:-LIHCEERB_cells_naive2.6176e-030.1938image
ENSG00000103199.12,ZNF500LIHCEAGB_cells_naive2.6672e-030.1935image
chr16:4749607-4751921:-LUADEERNeutrophils9.7927e-050.1865image
ENSG00000103199.12,ZNF500LUADEAGNeutrophils1.0101e-040.1862image
chr16:4749607-4751921:-LUSCEERT_cells_regulatory_(Tregs)3.0004e-02-0.1059image
ENSG00000103199.12,ZNF500LUSCEAGT_cells_regulatory_(Tregs)2.9903e-02-0.1060image
ENSG00000103199.12,ZNF500MESOEAGT_cells_CD4_memory_activated3.7958e-020.2418image
chr16:4749607-4751921:-OVEERB_cells_memory2.7333e-03-0.1750image
ENSG00000103199.12,ZNF500OVEAGB_cells_memory2.6855e-03-0.1754image
ENSG00000103199.12,ZNF500PAADEAGT_cells_gamma_delta5.4890e-030.2186image
chr16:4749607-4751921:-PCPGEERMonocytes9.5537e-030.1982image
ENSG00000103199.12,ZNF500PCPGEAGMonocytes9.4729e-030.1985image
chr16:4749607-4751921:-PRADEERT_cells_CD4_memory_resting4.2575e-040.1591image
ENSG00000103199.12,ZNF500PRADEAGT_cells_CD4_memory_resting5.0141e-040.1570image
ENSG00000103199.12,ZNF500READEAGT_cells_gamma_delta5.1078e-060.4906image
chr16:4749607-4751921:-SARCEERT_cells_CD4_memory_resting9.6907e-030.1650image
ENSG00000103199.12,ZNF500SARCEAGT_cells_CD4_memory_resting9.7920e-030.1647image
chr16:4749607-4751921:-STADEERNK_cells_resting2.3644e-020.1222image
ENSG00000103199.12,ZNF500STADEAGNK_cells_resting2.3174e-020.1224image
chr16:4749607-4751921:-TGCTEERDendritic_cells_resting2.3229e-02-0.1853image
ENSG00000103199.12,ZNF500TGCTEAGDendritic_cells_resting2.3530e-02-0.1849image
ENSG00000103199.12,ZNF500THCAEAGB_cells_naive1.1280e-020.1138image
ENSG00000103199.12,ZNF500THYMEAGNK_cells_activated1.1331e-050.4000image
chr16:4749607-4751921:-UCECEERB_cells_naive2.2839e-020.1766image
ENSG00000103199.12,ZNF500UCECEAGB_cells_naive2.4087e-020.1750image
chr16:4749607-4751921:-UCSEERMast_cells_resting3.0159e-02-0.2981image
ENSG00000103199.12,ZNF500UCSEAGMast_cells_resting3.0159e-02-0.2981image
ENSG00000103199.12,ZNF500UVMEAGMacrophages_M13.7224e-020.2551image


Top

6. Enriched editing regions and immune gene sets for ZNF500


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000103199.12,ZNF500ACCGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.7500e-050.4918image
ENSG00000103199.12,ZNF500BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.6189e-070.2798image
chr16:4749607-4751921:-BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEER1.6189e-070.2798image
chr16:4749607-4751921:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER1.4890e-130.2250image
ENSG00000103199.12,ZNF500BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.1590e-130.2236image
ENSG00000103199.12,ZNF500CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.9104e-070.3139image
chr16:4749607-4751921:-CESCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.9022e-070.3139image
ENSG00000103199.12,ZNF500CHOLGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.4601e-040.5819image
ENSG00000103199.12,ZNF500COADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG3.6971e-020.1455image
ENSG00000103199.12,ZNF500DLBCGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.4751e-050.5933image
chr16:4749607-4751921:-ESCAGSVA_HALLMARK_NOTCH_SIGNALINGEER5.1667e-030.2208image
ENSG00000103199.12,ZNF500ESCAGSVA_HALLMARK_NOTCH_SIGNALINGEAG3.4967e-030.2303image
chr16:4749607-4751921:-GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.7514e-03-0.2345image
ENSG00000103199.12,ZNF500GBMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG2.6625e-03-0.2353image
ENSG00000103199.12,ZNF500HNSCGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.0246e-070.2554image
ENSG00000103199.12,ZNF500KICHGSVA_HALLMARK_KRAS_SIGNALING_UPEAG7.5718e-030.3361image
chr16:4749607-4751921:-KIRCGSVA_HALLMARK_BILE_ACID_METABOLISMEER8.9661e-040.1770image
ENSG00000103199.12,ZNF500KIRCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG9.1042e-040.1768image
ENSG00000103199.12,ZNF500KIRPGSVA_HALLMARK_ANDROGEN_RESPONSEEAG8.2834e-100.3724image
chr16:4749607-4751921:-LGGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.7319e-09-0.2584image
ENSG00000103199.12,ZNF500LGGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.7319e-09-0.2584image
chr16:4749607-4751921:-LIHCGSVA_HALLMARK_PROTEIN_SECRETIONEER6.7229e-050.2549image
ENSG00000103199.12,ZNF500LIHCGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.5577e-050.2553image
ENSG00000103199.12,ZNF500LUADGSVA_HALLMARK_KRAS_SIGNALING_UPEAG9.4558e-090.2720image
chr16:4749607-4751921:-LUADGSVA_HALLMARK_KRAS_SIGNALING_UPEER8.7911e-090.2726image
ENSG00000103199.12,ZNF500LUSCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.0733e-040.1879image
chr16:4749607-4751921:-LUSCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.0845e-040.1878image
ENSG00000103199.12,ZNF500MESOGSVA_HALLMARK_MYC_TARGETS_V2EAG3.3853e-03-0.3364image
ENSG00000103199.12,ZNF500OVGSVA_HALLMARK_IL2_STAT5_SIGNALINGEAG1.6847e-040.2188image
chr16:4749607-4751921:-OVGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER1.7341e-040.2184image
ENSG00000103199.12,ZNF500PAADGSVA_HALLMARK_DNA_REPAIREAG8.0404e-04-0.2623image
ENSG00000103199.12,ZNF500PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.5330e-060.3590image
chr16:4749607-4751921:-PCPGGSVA_HALLMARK_PROTEIN_SECRETIONEER1.6182e-060.3582image
chr16:4749607-4751921:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER2.2051e-080.2501image
ENSG00000103199.12,ZNF500PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.5884e-080.2487image
ENSG00000103199.12,ZNF500READGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.5068e-040.4162image
chr16:4749607-4751921:-SARCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.1784e-040.2435image
ENSG00000103199.12,ZNF500SARCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2057e-040.2432image
chr16:4749607-4751921:-SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2396e-030.1538image
ENSG00000103199.12,ZNF500SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.1651e-030.1547image
chr16:4749607-4751921:-STADGSVA_HALLMARK_APICAL_SURFACEEER2.1489e-050.2272image
ENSG00000103199.12,ZNF500STADGSVA_HALLMARK_APICAL_SURFACEEAG2.2498e-050.2264image
chr16:4749607-4751921:-TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER2.3380e-030.2467image
ENSG00000103199.12,ZNF500TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.3895e-030.2462image
ENSG00000103199.12,ZNF500THCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.4333e-120.3111image
ENSG00000103199.12,ZNF500THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.0563e-080.5063image
ENSG00000103199.12,ZNF500UCECGSVA_HALLMARK_HEME_METABOLISMEAG4.5215e-050.3111image
chr16:4749607-4751921:-UCECGSVA_HALLMARK_HEME_METABOLISMEER3.2901e-050.3164image
chr16:4749607-4751921:-UCSGSVA_HALLMARK_MITOTIC_SPINDLEEER4.6740e-050.5289image
ENSG00000103199.12,ZNF500UCSGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.6740e-050.5289image
ENSG00000103199.12,ZNF500UVMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.1640e-030.3683image


Top

7. Enriched editing regions and drugs for ZNF500


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000103199.12,ZNF500ACCBortezomibEAG7.3518e-040.4053image
ENSG00000103199.12,ZNF500BLCABMS.536924EAG3.2622e-040.1940image
chr16:4749607-4751921:-BLCABMS.536924EER3.2622e-040.1940image
ENSG00000103199.12,ZNF500BRCAAZD6482EAG2.3581e-08-0.1712image
chr16:4749607-4751921:-BRCAAZD6482EER1.5267e-08-0.1735image
chr16:4749607-4751921:-CESCBMS.536924EER1.5568e-060.2917image
ENSG00000103199.12,ZNF500CESCBMS.536924EAG1.5552e-060.2917image
ENSG00000103199.12,ZNF500CHOLEHT.1864EAG6.6205e-030.4504image
ENSG00000103199.12,ZNF500COADGSK269962AEAG1.3332e-020.1722image
ENSG00000103199.12,ZNF500DLBCJNK.Inhibitor.VIIIEAG6.7430e-05-0.5874image
ENSG00000103199.12,ZNF500GBMBI.2536EAG8.0874e-060.3436image
chr16:4749607-4751921:-GBMBI.2536EER8.1847e-060.3434image
ENSG00000103199.12,ZNF500HNSCDMOGEAG1.1564e-08-0.2886image
ENSG00000103199.12,ZNF500KICHBortezomibEAG8.1060e-030.3334image
ENSG00000103199.12,ZNF500KIRCGW843682XEAG3.4093e-080.2901image
chr16:4749607-4751921:-KIRCGW843682XEER2.1151e-080.2943image
ENSG00000103199.12,ZNF500KIRPAZD6244EAG7.8139e-070.3035image
chr16:4749607-4751921:-LGGAZD6482EER6.8367e-12-0.2930image
ENSG00000103199.12,ZNF500LGGAZD6482EAG6.8367e-12-0.2930image
chr16:4749607-4751921:-LIHCBMS.509744EER1.1798e-050.2792image
ENSG00000103199.12,ZNF500LIHCBMS.509744EAG1.1733e-050.2793image
ENSG00000103199.12,ZNF500LUADBMS.708163EAG9.5898e-05-0.1868image
chr16:4749607-4751921:-LUADBMS.708163EER8.9310e-05-0.1876image
ENSG00000103199.12,ZNF500LUSCAZD6482EAG1.4624e-02-0.1191image
chr16:4749607-4751921:-LUSCAZD6482EER1.4672e-02-0.1190image
ENSG00000103199.12,ZNF500MESOAZD6482EAG1.7118e-04-0.4234image
ENSG00000103199.12,ZNF500OVBI.2536EAG5.3331e-030.1629image
chr16:4749607-4751921:-OVBI.2536EER5.6388e-030.1619image
ENSG00000103199.12,ZNF500PAADMG.132EAG8.2433e-040.2626image
chr16:4749607-4751921:-PCPGCamptothecinEER8.1807e-060.3346image
ENSG00000103199.12,ZNF500PCPGCamptothecinEAG8.0200e-060.3350image
ENSG00000103199.12,ZNF500PRADBMS.509744EAG7.4625e-070.2218image
chr16:4749607-4751921:-PRADBMS.509744EER6.3020e-070.2235image
ENSG00000103199.12,ZNF500READBMS.708163EAG7.1407e-06-0.4840image
chr16:4749607-4751921:-SARCGDC.0449EER3.1787e-070.3196image
ENSG00000103199.12,ZNF500SARCGDC.0449EAG3.2731e-070.3193image
chr16:4749607-4751921:-SKCMBMS.536924EER2.7349e-040.1735image
ENSG00000103199.12,ZNF500SKCMBMS.536924EAG3.3511e-040.1710image
chr16:4749607-4751921:-STADEmbelinEER1.8326e-04-0.2007image
ENSG00000103199.12,ZNF500STADEmbelinEAG3.4575e-04-0.1918image
chr16:4749607-4751921:-TGCTABT.263EER2.3545e-03-0.2466image
ENSG00000103199.12,ZNF500TGCTABT.263EAG2.3817e-03-0.2463image
ENSG00000103199.12,ZNF500THCAAKT.inhibitor.VIIIEAG1.1422e-12-0.3124image
ENSG00000103199.12,ZNF500THYMCMKEAG3.8613e-090.5191image
chr16:4749607-4751921:-UCECAZD.2281EER2.1243e-060.3584image
ENSG00000103199.12,ZNF500UCECAZD.2281EAG3.5978e-060.3508image
ENSG00000103199.12,ZNF500UCSAZD6482EAG7.1518e-05-0.5178image
chr16:4749607-4751921:-UCSAZD6482EER7.1518e-05-0.5178image
ENSG00000103199.12,ZNF500UVMBMS.536924EAG9.2266e-040.3956image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType